Navigation Links
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Date:6/6/2008

suance under the Company's certificate of

incorporation, as required by the transactional documents in our recent

financing;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.

CONTACT:

Genta Investor Relations

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Faced with increasing challenges such as costly treatments ... the global healthcare industry today is gradually transforming ... or significantly changing the course of a disease, ... medicine as a viable alternative. Regenerative ... with the potential to resolve unmet medical needs ...
(Date:7/27/2015)... ... July 27, 2015 , ... This is a professional and ... basic overview of the industry including definitions, classifications, applications and industry chain structure. ... competitive landscape analysis, and key regions development status. Development policies and plans are ...
(Date:7/27/2015)... 27, 2015 Research presented at the 2015 ... on the studies that led to a fingerprick Ebola ... this disease to receive approval from the World Health ... Ebola,s grip on West Africa ... healthcare workers to isolate and treat these patients much ...
(Date:7/27/2015)... NEW YORK , July 27, 2015 ... organizations and startups share information and develop new technology ... The Sachs Policy Group (SPG), a leader in health ... members will now engage in a collaborative innovation process ... through the latest trends in public policy, health care ...
Breaking Biology Technology:Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today ... of SYMLIN® (pramlintide acetate) injection in patients with type ... completed clinical studies. The data, which will be presented ... of the American Diabetes Association (ADA) in San Diego, ...
... June 24, 2011 /PRNewswire-iReach/ -- Harbour ... today the completion of a non-exclusive research and ... a global pharmaceutical company, to generate and develop ... chains(H2L2) using one of Harbour,s transgenic mouse antibody ...
... 24, 2011 ,   ... 2511) investigated the efficacy and safety of,the monoclonal ... This study showed that in patients with,severe AAV ... and,maintenance over a period of 18 months proved ...
Cached Biology Technology:Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps 2Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps 3Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps 4Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps 5Harbour Antibodies BV Signs Research and Licence Agreement With Lilly 2ERA-EDTA Congress 2011: Late Breaking Clinical Trials I 2
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... mice exposed to Bisphenol A through their mother,s diet during ... activity and had leaner body mass than those not exposed ... of Public Health have discovered. BPA is a chemical ... cash register receipts. It once was in many hard plastic ...
... from the Jurassic period challenges widely accepted theories on the ... Lecturer in Vertebrate Palaeontology at the University of Southampton, the ... length which pre-dates bird-like dinosaurs that birds were long thought ... it has become accepted among palaeontologists that birds evolved from ...
... of any use, one must first be able to find it. ... too much of it. We are helped by thousands of computers ... digest and comprehend it. In this "ocean" of information, open access ... content that can be harvested, extracted, sorted out and indexed by ...
Cached Biology News:Female mice exposed to BPA by mothers show unexpected characteristics 2Female mice exposed to BPA by mothers show unexpected characteristics 3Pensoft Publishers integrate their journal platform with OpenAIRE 2
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
... 400 Spun Columns, 10. *SizeSep 400 Spun ... 400 base pairs in length. - ... and pre-equilibrated in distilled water containing 0.15% Kathon ... ~ 400 base pairs. *Extremely useful ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Biology Products: